Taiwan Showcases Biotech Innovations at BioJapan 2025

The Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of Taiwan announced a significant initiative as it leads a delegation of 16 biotech industry partners to the BioJapan 2025 event in Yokohama, taking place from October 8-10, 2025. This participation aims to highlight the strengths of Taiwan’s biotech ecosystem and facilitate collaboration with Japanese companies to advance the future of biotechnology innovation.

Showcasing Taiwan’s Biotech Ecosystem

At BioJapan 2025, the Taiwan Pavilion will present cutting-edge advancements in several high-growth sectors, including regenerative medicine, AI healthcare, precision health, and contract development and manufacturing (CDMO). This platform will allow Taiwanese companies to demonstrate their unique capabilities and foster discussions on potential partnerships with Japanese firms.

Recent collaborations illustrate the growing influence of Taiwanese biotech companies in Japan. For instance, in 2024, Japan’s CBC became the official distributor for Taiwan’s TBMC, marking a significant step in expanding its market presence. Additionally, Leeuwenhoek successfully launched its Flora Le Light Synbiotic in Japan, further solidifying Taiwan’s foothold in the region.

Key Partnerships and Innovations

This year has seen notable partnerships emerge, such as Amaran Biotech joining forces with Nippon Fine Chemical to enhance CDMO manufacturing technology services for nanoparticle-based drugs in both countries. Taiwanese and Japanese collaborations have yielded several advancements, including AM Biotech‘s high-purity targeted exosomes being officially registered with the Japan Cosmetic Industry Association. These exosomes have now expanded their application from cosmetics to regenerative medicine.

Another significant achievement comes from LumiSTAR, which has been selected for Takeda Pharmaceutical‘s COCKPI-T® program, aimed at advancing innovation in drug discovery and development.

As further evidence of the strengthening ties, one of the delegation members, Creative Life Science, plans to sign a memorandum of understanding (MOU) with Myoridge to combine resources in cell culture and production channels. This collaboration seeks to unlock new opportunities in regenerative medicine.

The Taiwanese delegation will also visit Astellas Pharma, a leading Japanese multinational pharmaceutical company, to tour its innovative SakuLab facility. This visit aims to foster collaboration in cell therapy and bioprocessing, further bridging the gap between Taiwanese biotechnology and Japanese pharmaceutical advancements.

The complete list of delegation members and additional information about their initiatives can be found at this link. Media inquiries should be directed to Janet Chung at [email protected].